Skip to main content
Premium Trial:

Request an Annual Quote

Bioinfra, 20/20 GeneSystems Ink Deal for US Sales of Multi-Cancer Test

NEW YORK — Bioinfra Life Sciences said Thursday it had signed an exclusive licensing agreement for 20/20 GeneSystems to sell Bioinfra's technology in the US market.

Korean firm Bioinfra and Maryland-based 20/20 GeneSystems have both developed assays for the early detection of multiple cancers. Bioinfra said its test, which is available for less than $200, improves diagnostic accuracy by incorporating measures of several inflammatory biomarkers, and the results include algorithm-driven risk assessments of individual tumor types rather than overall cancer risk.

The companies said 20/20 plans to add Bioinfra's technology to a premium version of 20/20's OneTest blood-based assay for early detection of multiple cancers, and that test, anticipated to become available in Q4 2022, is expected to cost less than $300. 20/20 President and CEO Jonathan Cohen said the partnership will improve the diagnostic accuracy and clinical value of the OneTest assay.

Bioinfra will receive upfront payments and test volume-based royalties. Further details of the agreement were not disclosed.

The deal is Bioinfra's first outside Korea, and the firm is exploring opportunities in other countries, it said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.